Cipepofol is under clinical development by Sichuan Haisco Pharmaceutical and currently in Phase III for General Anesthetic Effect. According to GlobalData, Phase III drugs for General Anesthetic Effect does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cipepofol LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cipepofol overview
Cipepofol (Si Shu Ning, Cyclopofol) is a GABAA receptor agonist and an anesthetic sedative. It is formulated as solution for intravenous route of administration. Si Shu Ning is indicated for the induction of sedation, general anesthesia for gastrointestinal endoscopy and induction and maintenance of general anesthesia.
See Also:
HSK-3486 is under development for general anesthetic effect and sedation. It is a 2, 6-disubstituted alkylphenol. It is administered through intravenous bolus route. The drug candidate acts by targeting the GABAA receptor (Gamma-aminobutyric acid type A receptor).
Sichuan Haisco Pharmaceutical overview
Sichuan Haisco Pharmaceutical (Haisco) is pharmaceutical company. The company’s areas of interests include drug development, manufacturing, and sales. Haisco is headquartered in Chengdu, Sichuan, China.
For a complete picture of Cipepofol’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
